ISO 27001 for pharmaceutical manufacturers.
Pharma already operates GxP-validated IT under GMP Annex 11 and GAMP 5. ISO 27001 adds an ISMS governance layer — board-level accountability, systematic risk management, supply chain. Matproof unifies GxP validation evidence with ISO 27001 control evidence.
Why this matters now
Ransomware in pharma 2023-2025 caused production disruption and regulatory scrutiny. EMA inspections now routinely reference cyber maturity. ISO 27001 is becoming the industry baseline expectation alongside cGMP.
- GxP-validated systems make changes slow and expensive
- Production-floor IT (MES, SCADA) is OT/ICS-heavy and hard to patch
- Clinical trial data flows create GCP + GDPR + IT security triple obligation
- Contract manufacturers and API suppliers introduce complex supply-chain risk
How Matproof covers ISO 27001 for Pharmaceutical Manufacturing
Annex 11 to ISO 27001 mapping
GAMP 5 categories and Annex 11 IT controls mapped to ISO 27001:2022 Annex A. Validation evidence serves both GMP and ISO audits.
OT/ICS scope with compensating controls
MES, SCADA, BAS (building automation) scoped with risk-accepted compensating controls documented in SoA. Auditors familiar with pharma accept this approach.
Clinical trial data flow
GCP audit trails + ISO 27001 access controls + GDPR records of processing — one unified data model produces all three sets of artefacts.
CMO / API supplier management
Contract manufacturers and API suppliers mapped as ISO 27001 suppliers with GxP audit status + cyber posture combined in one vendor register.
In scope
- Pharmaceutical manufacturers (human medicines)
- Biologics and advanced-therapy manufacturers (ATMPs)
- Veterinary pharmaceuticals
- API producers and intermediates
- Contract development and manufacturing organizations (CDMOs)
- Clinical trial sponsors with internal operations
Frequently asked questions
Does GMP Annex 11 compliance satisfy ISO 27001?+
Partially. Annex 11 IT validation covers GxP-relevant systems with strong access control, audit trails, change management, backup, and DR. Overlap with ISO 27001 Annex A is ~60%. Gaps: board governance, risk management scope (broader than IT), supply-chain controls, training obligations broader than GxP roles. Matproof structures both from a single control library.
How do we handle legacy production systems that can't be fully patched?+
Classic pharma problem. Approach: document in asset register, assess risk, apply network segmentation and access control, document management approval for risk acceptance, schedule monitored end-of-life planning. Auditors accept this pattern when the treatment is defensible and monitored.
What about cloud-hosted GxP systems?+
Cloud GxP requires provider qualification (SLA, validated infrastructure, data residency for EU patients). Major cloud providers (AWS, Azure, GCP) have GxP-specific compliance packages. ISO 27001 subservice-org carve-out applies — collect their reports, track annually, document complementary controls you must implement.
Ready to start with ISO 27001?
30-minute demo tailored to Pharmaceutical Manufacturing. We show you exactly how Matproof covers ISO 27001 for your sector.